AI memory therapy is no longer a concept. It is here, clinically validated, and already helping dementia patients feel less lonely and more connected.

In this episode of Clinical Capital Conversations, Peter M. Kovacs speaks with Kompanion Care founder Peter Markus about Lilia, an AI-powered therapeutic platform that combines reminiscence therapy, family-generated memories, and digital biomarkers to deliver real clinical impact.

We explore:

• How personal loss shaped the company

• Why AI can scale proven psychotherapies

• How clinical validation creates trust

• Why reimbursement is the true growth path

• How digital biomarkers will transform early detection

If you want to understand where dementia care, digital therapeutics, and AI-driven monitoring are heading, this conversation is essential.

Timecode:

00:00 Introduction and Guest Introduction

00:23 Peter Markus's Background and Career Journey

01:26 The Birth of Kompanion Care

04:31 Innovative Technology Behind Lilia Platform

11:41 Challenges and Importance of Medical Software

15:23 Current Progress and Future Plans

22:17 Investment and Market Strategy

37:28 Conclusion and Final Thoughts

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Péter Márkus: https://www.linkedin.com/in/pmarkus/

Kompanion Care: https://www.kompanioncare.com/